North America Kidney Cancer Therapeutics & Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.80 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Kidney Cancer Therapeutics & Diagnostics Market Analysis
The North America Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.8% during the forecast period. The major factors driving the growth of the market in the North America region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.
According to GLOBOCAN 2018, in 2018, there were about 60,336 new kidney cancer cases and the mortality was approximately 15,333 cases in the United States.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the North America kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.
North America Kidney Cancer Therapeutics & Diagnostics Market Trends
This section covers the major market trends shaping the North America Kidney Cancer Therapeutics & Diagnostics Market according to our research experts:
Clear cell RCC Segment is Expected to Hold Major Market Share in the North America Kidney Cancer Therapeutics & Diagnostics Market
Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles.
As per the National Cancer Institute of the United States, in adults, ccRCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma cases. ccRCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases.
For people without symptoms, these tumors can be discovered if the person has an imaging test as well. Another method to detect ccRCC is biopsy. To check if the tumor is ccRCC, the physician performs a biopsy, taking a small sample from the tumor with a needle. The sample is studied under the microscope to see what kind of tumor it is.
Some targeted therapies that are used to treat clear cell renal carcinoma include cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib. Hence, with high prevalence of the disease and presence of diagnostic procedures and treatment therapies, the segment is expected to witness growth.
North America Kidney Cancer Therapeutics & Diagnostics Industry Overview
The North America Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated competitive. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market. Some of the companies which are currently dominating the market are Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Abbott Laboratories, Amgen Inc, and Seattle Genetics.
North America Kidney Cancer Therapeutics & Diagnostics Market Leaders
-
Pfizer Inc
-
F. Hoffmann-La Roche Ltd
-
Bayer AG
-
Novartis AG
-
Amgen Inc
*Disclaimer: Major Players sorted in no particular order
North America Kidney Cancer Therapeutics & Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Number of Kidney Cancer Cases
- 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
-
4.3 Market Restraints
- 4.3.1 High Cost Associated with Treatment
- 4.3.2 Preference for Generic Drugs
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
- 5.1.1 Clear cell RCC
- 5.1.2 Papillary RCC
- 5.1.3 Chromophobe RCC
- 5.1.4 Urothelial carcinoma/Transitional cell carcinoma
- 5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
-
5.2 By Component
- 5.2.1 Drugs
- 5.2.1.1 Therapeutic Class
- 5.2.1.1.1 Targeted Therapy
- 5.2.1.1.2 Immunotherapy
- 5.2.1.1.3 Other Therapeutic Class
- 5.2.1.2 Pharmacologic Class
- 5.2.1.2.1 Angiogenesis Inhibitors
- 5.2.1.2.2 Monoclonal Antibodies
- 5.2.1.2.3 mTOR Inhibitors
- 5.2.1.2.4 Cytokine Immunotherapy (IL-2)
- 5.2.2 Diagnostics
- 5.2.2.1 Biopsy
- 5.2.2.2 Imaging Tests
- 5.2.2.3 Blood Tests
- 5.2.2.4 Other Diagnostics
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc
- 6.1.2 F. Hoffmann-La Roche Ltd
- 6.1.3 Bayer AG
- 6.1.4 Novartis AG
- 6.1.5 Amgen Inc
- 6.1.6 Abbott Laboratories
- 6.1.7 Cerulean Pharma Inc
- 6.1.8 Eisai co Ltd
- 6.1.9 Seattle Genetic
- 6.1.10 GlaxoSmithKline PL
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
North America Kidney Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The North America kidney cancer therapeutics & diagnostics market is segmented by cancer type, component and geography.
North America Kidney Cancer Therapeutics & Diagnostics Market Research FAQs
What is the current North America Kidney Cancer Therapeutics & Diagnostics Market size?
The North America Kidney Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in North America Kidney Cancer Therapeutics & Diagnostics Market?
Pfizer Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG and Amgen Inc are the major companies operating in the North America Kidney Cancer Therapeutics & Diagnostics Market.
What years does this North America Kidney Cancer Therapeutics & Diagnostics Market cover?
The report covers the North America Kidney Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Kidney Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
North America Kidney Cancer Therapeutics & Diagnostics Industry Report
Statistics for the 2024 North America Kidney Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Kidney Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
